Breaking News
Get 50% Off 0
📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-Earnings Read more
Close

Biogen Inc (0R1B)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
225.31 +0.00    +0.00%
19/07 - Real-time Data. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 223.49 - 227.13
Type:  Equity
Market:  United Kingdom
ISIN:  US09062X1037 
SEDOL:  B0Z5300
Biogen 225.31 +0.00 +0.00%

Biogen Company Profile

 
Read the Biogen company profile to learn more about the business and the management team. View Biogen Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

8725

Equity Type

ORD

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 225 Binney Street
Cambridge, 02142
United States
Phone 617 679 2000
Fax -

Top Executives

Name Age Since Title
Christopher A. Viehbacher 62 2022 President, CEO & Director
Caroline D. Dorsa 64 2010 Independent Chair of the Board
Maria C. Freire 69 2021 Independent Director
Eric K. Rowinsky 66 2010 Independent Director
Stephen A. Sherwin 74 2010 Independent Director
Jesus B. Mantas 54 2019 Independent Director
William A. Hawkins 69 2019 Independent Director
Monish D. Patolawala 52 2024 Independent Director
Susan Langer 32 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BIIB Price Commentary

Write your thoughts about Biogen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anon Anon
Anon Anon Sep 28, 2022 14:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hit jackpot again
Anon Anon
Anon Anon Jun 07, 2021 18:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hit the jackpot with this one kaching
Chia Fong ying
Chia Fong ying Feb 01, 2021 14:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Biib is going to give eps $30.21/share,is good buy for long term.
Chia Fong ying
Chia Fong ying Jan 30, 2021 0:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong buy, biib upgrade target price to $385..stock will up again on next Monday.
Chia Fong ying
Chia Fong ying Jan 26, 2021 15:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eps 30.21/share, is a good buy..
Chia Fong ying
Chia Fong ying Jan 25, 2021 3:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Biib is very good stock, can invest for long term. Share will up soon, eps will given on Feb 03,means you need to hold the stock on around Feb 1st
Best Solution
Best Solution Feb 06, 2020 18:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bull...call
Stephen Smyth
Stephen Smyth Jan 30, 2020 20:08
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why has the stock gone down???
Joseph Karam
Joseph Karam Apr 03, 2019 15:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
where do u see biib on the short run ??!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email